RPC 4046

Drug Profile

RPC 4046

Alternative Names: ABT-308; RPC-4046

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie; Receptos
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action Interleukin 13 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Eosinophilic oesophagitis
  • Discontinued Allergic asthma

Most Recent Events

  • 09 Jan 2017 Celgene plans a phase III trial for Eosinophilic oesophagitis
  • 15 Oct 2016 Pharmacodynamics and adverse event data from a phase II trial in Eosinophilic-oesophagitis presented at the 24th United European Gastroenterology Week (UEGW-2016)
  • 11 Feb 2015 RPC 4046 receives Orphan Drug status for Eosinophilic oesophagitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top